Ghrelin Administration for XXXX : A Randomized Dose-Comparison Trial.

@entity1 @entity353 @entity26 @entity358 @entity1576 @entity2057
BACKGROUND: Repeated ghrelin administration leads to improvements in symptoms, @entity2057 and exercise tolerance in cachectic @entity1 with @entity358 . We investigated the optimal ghrelin dose for underweight @entity1 with @entity1576 . METHODS: In this multicenter, randomized, dose-comparison exploratory study, 44 cachectic @entity1 with @entity1576 were randomly assigned pulmonary rehabilitation with intravenous twice-daily administration of 1 or 2   g/kg ghrelin for 3  weeks. The primary endpoint was improvement in 6-min walking distance (6MWD). The secondary endpoint was change in peak [Formula: see text]O2. RESULTS: Twenty-one @entity1 were assigned to the 1   g/kg ghrelin group and 23 to the 2   g/kg ghrelin group. Change from baseline 6MWD after treatment was similar between groups(1   g/kg: 53.9  m, 2   g/kg: 53.9  m, p  =  0.99). Mean change in peak [Formula: see text]O2 was significantly greater in the 2   g/kg group (63.1  ml/min) than in the 1   g/kg group (-63.8  ml/min, p  =  0.048). Food intake and lean body mass significantly increased in both groups, and the St. George Respiratory Questionnaire score, body weight, and body mass index were remarkably improved in only the 2   g/kg group, although there was no significant difference between groups. No treatment-related serious events were reported for either group. CONCLUSION: Improvements in the @entity26 uptake capacity were greater in @entity1 receiving 2   g/kg ghrelin twice daily for 3  weeks than in those receiving 1   g/kg, although exercise tolerance was similar between groups at the end of the 3-week treatment period. Thus, a twice daily dose of 2   g/kg ghrelin is recommended over 1   g/kg ghrelin for @entity1 with @entity1576 and @entity353 .
